SCHEDULE 13G: Key Insiders Disclose Significant 13.7% Stake in Aardvark Therapeutics

Tien-Li Lee and Jane Wu Lee have disclosed a combined beneficial ownership of 13.7% of Aardvark Therapeutics, Inc.'s common stock.

Summary

• Tien-Li Lee and Jane Wu Lee, identified as Reporting Persons, have filed a Schedule 13G indicating beneficial ownership of 2,983,724 shares of Aardvark Therapeutics, Inc. common stock.
• This aggregate amount represents 13.7% of the Issuer's common stock outstanding as of March 31, 2025.
• The ownership is comprised of 1,496,175 shares directly owned by Tien-Li Lee, 1,474,028 shares directly owned by Jane Wu Lee, and 13,521 shares issuable to Tien-Li Lee upon exercise of options within 60 days of March 31, 2025.
• As spouses, Tien-Li Lee and Jane Wu Lee are deemed to have shared voting and dispositive power over all 2,983,724 shares.
• The percentage of class is calculated based on 21,695,920 shares outstanding as of March 31, 2025, as reported in the Issuer's Form 10-Q filed on May 14, 2025, plus the 13,521 exercisable options.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership, not a performance or strategic update. The significant insider ownership could be viewed positively by some investors as a sign of confidence.

Positives

• The disclosure of a significant 13.7% beneficial ownership by key individuals (Tien-Li Lee and Jane Wu Lee), who appear to be insiders given their shared address with the company, can signal strong confidence in Aardvark Therapeutics' future prospects.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by individuals and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The beneficial ownership is shared between Tien-Li Lee and Jane Wu Lee, who are spouses, and are deemed to have shared voting and dispositive power over each other's directly held shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant insider ownership, which can influence investor perception of management alignment and confidence.

Key Dates

Keywords

Aardvark Therapeutics, beneficial ownership, Schedule 13G, common stock, insider ownership, Tien-Li Lee, Jane Wu Lee, SEC filing